SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-009600
Filing Date
2023-03-30
Accepted
2023-03-30 08:05:26
Documents
15
Period of Report
2023-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36951
2 ex99-1.htm EX-99.1 96906
3 ex99-1_001.jpg GRAPHIC 14877
4 ex99-1_002.jpg GRAPHIC 170204
  Complete submission text file 0001493152-23-009600.txt   580236

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE dare-20230330.xsd EX-101.SCH 3245
6 XBRL LABEL FILE dare-20230330_lab.xml EX-101.LAB 34916
7 XBRL PRESENTATION FILE dare-20230330_pre.xml EX-101.PRE 22801
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3738
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

IRS No.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 23777217
SIC: 2834 Pharmaceutical Preparations